title: Clindamycin and nicotinic neuromuscular transmission.
abstract: Upon clindamycin treatment a patient with Parkinson's disease showed marked tremor improvement which may be explained by clindamycin's ability to inhibit in-vitro nicotinergic, but not muscarinic signal transmission.
authors.forename: J
authors.initials: J
authors.lastname: Schulze
authors.forename: M
authors.initials: M
authors.lastname: Toepfer
authors.forename: K C
authors.initials: KC
authors.lastname: Schroff
authors.forename: S
authors.initials: S
authors.lastname: Aschhoff
authors.forename: J
authors.initials: J
authors.lastname: Remien
authors.forename: W
authors.initials: W
authors.lastname: Müller-Felber
authors.forename: S
authors.initials: S
authors.lastname: Endres
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D006801:Humans; D051379:Mice; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects; D009435:Synaptic Transmission / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D002981:Clindamycin